VanEck Associates
ONC

VanEck Associates’s BeOne Medicines Ltd ONC Stock Holding History

VanEck Associates’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.7M Sell
55,002
-53,303
-49% -$15.7M 0.01% 499
2026
Q1 		$32.2M Buy
108,305
+18,295
+20% +$5.92M 0.02% 341
2025
Q4 		$27.3M Sell
90,010
-8,576
-9% -$2.81M 0.02% 330
2025
Q3 		$33.6M Buy
98,586
+10,640
+12% +$3.23M 0.03% 267
2025
Q2 		$21.3M Buy
87,946
+7,516
+9% +$1.84M 0.02% 333
2025
Q1 		$21.9M Sell
80,430
-8,612
-10% -$2.01M 0.03% 307
2024
Q4 		$16.4M Buy
89,042
+50,154
+129% +$10.2M 0.02% 356
2024
Q3 		$8.6M Sell
38,888
-56,689
-59% -$10.2M 0.01% 492
2024
Q2 		$13.6M Buy
95,577
+7,816
+9% +$1.2M 0.02% 352
2024
Q1 		$13.7M Buy
87,761
+5,065
+6% +$816K 0.02% 335
2023
Q4 		$14.9M Sell
82,696
-15,454
-16% -$2.8M 0.03% 295
2023
Q3 		$17.7M Buy
98,150
+957
+1% +$189K 0.04% 257
2023
Q2 		$17.3M Buy
97,193
+20,651
+27% +$4.76M 0.04% 268
2023
Q1 		$16.5M Sell
76,542
-16,409
-18% -$3.94M 0.04% 270
2022
Q4 		$20.4M Buy
92,951
+37,698
+68% +$6.91M 0.05% 237
2022
Q3 		$7.45M Sell
55,253
-44,713
-45% -$7.68M 0.02% 365
2022
Q2 		$16.2M Buy
99,966
+6,637
+7% +$1.04M 0.04% 265
2022
Q1 		$17.6M Buy
93,329
+42,417
+83% +$9.02M 0.04% 274
2021
Q4 		$13.8M Sell
50,912
-1,910
-4% -$645K 0.03% 311
2021
Q3 		$19.2M Sell
52,822
-10,994
-17% -$3.59M 0.05% 249
2021
Q2 		$21.9M Buy
63,816
+2,845
+5% +$942K 0.05% 240
2021
Q1 		$21.2M Buy
60,971
+30,534
+100% +$10.1M 0.06% 217
2020
Q4 		$7.87M Sell
30,437
-120,539
-80% -$33.2M 0.02% 340
2020
Q3 		$43.2M Sell
150,976
-75,636
-33% -$17.8M 0.14% 126
2020
Q2 		$42.7M Buy
226,612
+5,538
+3% +$901K 0.15% 121
2020
Q1 		$27.2M Buy
221,074
+46,807
+27% +$7.32M 0.14% 118
2019
Q4 		$28.9M Sell
174,267
-3,395
-2% -$564K 0.11% 146
2019
Q3 		$21.8M Buy
177,662
+65,169
+58% +$8.66M 0.1% 160
2019
Q2 		$13.9M Sell
112,493
-14,433
-11% -$1.83M 0.07% 195
2019
Q1 		$16.8M Buy
+126,926
New +$17.1M 0.08% 177

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VanEck Associates's ONC Position: Q2 2026 in Review

VanEck Associates reduced its BeOne Medicines Ltd (ONC) stake by 49% in Q2 2026, selling an estimated $15.7M and leaving 55,002 shares worth $15.7M. The position accounts for 0.01% of the portfolio, ranked #499.

VanEck Associates first reported a position in ONC in Q1 2019 and has held it in 30 quarters since. The position peaked at $43.2M in Q3 2020. 283 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • VanEck Associates held 55,002 shares of BeOne Medicines Ltd worth $15.7M as of Q2 2026.
  • VanEck Associates sold 53,303 BeOne Medicines Ltd shares in Q2 2026, an estimated $15.7M.
  • BeOne Medicines Ltd made up 0.01% of VanEck Associates's portfolio in Q2 2026, its #499 holding.
  • VanEck Associates first reported a position in BeOne Medicines Ltd in Q1 2019 and has held it in 30 quarters since.
  • VanEck Associates's BeOne Medicines Ltd position peaked at $43.2M in Q3 2020.
  • 283 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.